November 12, 2021 — Orchestra BioMed Inc. announced multiple presentations of long-term clinical results and ISH ...
Hypertension
This page includes news and new technology on hypertension. The condition is caused by abnormally high blood pressure that causes excess force and pressure of the blood against the artery walls. Long-term, this can cause damage the vessels and contributes to heart disease. Therapies include antihypertensive medications such as diurestics and renal denervation therapy.
November 9, 2021 — Six-month outcomes from the randomized RADIANCE-HTN TRIO Trial comparing endovascular ultrasound ...
November 09, 2021
August 3, 2021 — Long-term follow-up data on hypertensive patients from the control group of the MODERATO II study who ...
August 03, 2021
Feature | Hypertension | By Dave Fornell, Editor
May 16, 2021 — Two months after undergoing renal denervation (RDN) with the ReCor Paradise renal denervation system ...
May 16, 2021
December 9, 2020 — SoniVie, an Israeli company developing the Therapeutic Intra-Vascular Ultrasound (TIVUS) System to ...
December 09, 2020
July 15, 2020 – Omron Healthcare Inc. and Mount Sinai Health System, New York City’s largest academic medical system ...
July 15, 2020
June 26, 2020 – New data from the Global SYMPLICITY Registry (GSR) showed that renal denervation (RDN) with the ...
June 26, 2020
April 30, 2020 — A large study in adolescents and children, some as young as 3 years of age, shows a link between ...
April 30, 2020
April 8, 2020 — There has been debate in the past month or so during the novel coronavirus (COVID-19) pandemic whether ...
April 08, 2020
April 1, 2020 — Three months after undergoing renal denervation (RDN), patients with untreated high blood pressure had ...
April 01, 2020April 1, 2020 — Three months after undergoing renal denervation (RDN), patients with untreated high blood pressure had ...
April 01, 2020
News | Coronavirus (COVID-19) | Dave Fornell, Editor
March 16, 2020 — The European Society of Cardiology (ESC) issued a statement March 13 recommending in novel coronavirus ...
March 16, 2020
February 27, 2020 — Aria CV Inc. completed a $31 million Series B round of financing to fund its first clinical study in ...
February 27, 2020
February 7, 2020 — The U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the Aria ...
February 07, 2020
October 10. 2019 — Late-breaking results from its MODERATO II double-blind, randomized study of BackBeat Cardiac ...
October 10, 2019© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now